%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 15 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 13 0 R /GS2 14 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260402140112+00'00') /ModDate (D:20260402140112+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 11 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 4884 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces Fast Track Designation)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Granted by the FDA to CFI-400945 for the Treatment of Acute)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(Myeloid Leukemia)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(NEW YORK and HONG KONG, April 26, 2022 /PRNewswire/ ?? Treadwell Therapeutics, a clinical-)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(stage biotechnology company developing novel medicines for unmet needs in cancer, announced)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(today that the U.S. Food and Drug Administration \(FDA\) has granted Fast Track Designation to CFI-)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(400945, a first in class inhibitor of Polo-like kinase 4 \(PLK4\), for the treatment of adult patients with)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(relapsed or refractory Acute Myeloid Leukemia \(AML\).)] TJ ET BT 35.000 583.757 Td /F1 12.0 Tf [(??Although several exciting new classes of medicines have emerged in the past decade for patients)] TJ ET BT 35.000 569.105 Td /F1 12.0 Tf [(with AML, there still remains an unmet need for certain patient segments, where survival rates remain)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(low,?)] TJ ET BT 69.680 554.453 Td /F1 12.0 Tf [()] TJ ET BT 73.016 554.453 Td /F1 12.0 Tf [( said Dr. Michael Tusche, Treadwell co-CEO. ??CFI-400945, has shown encouraging signs of)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(monotherapy activity in AML patients with adverse cytogenetics. We are grateful for the Fast Track)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(Designation for this exciting program, and look forward to frequent interactions with the FDA to chart)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(our regulatory path forward, as we continue the development of ??945 in leukemia.?)] TJ ET BT 495.236 510.497 Td /F1 12.0 Tf [()] TJ ET BT 35.000 483.845 Td /F1 12.0 Tf [(Fast Track designation seeks to streamline the development and accelerate the review of new agents)] TJ ET BT 35.000 469.193 Td /F1 12.0 Tf [(with potential to treat serious or life-threatening diseases and that potentially address an unmet medical)] TJ ET BT 35.000 454.541 Td /F1 12.0 Tf [(need. Drugs that are granted this designation can have more frequent interactions with the FDA, as well)] TJ ET BT 35.000 439.889 Td /F1 12.0 Tf [(as potential pathways for expedited approval.)] TJ ET BT 35.000 409.204 Td /F3 14.0 Tf [(About AML)] TJ ET BT 35.000 380.014 Td /F1 12.0 Tf [(AML is a disease characterized by uncontrolled proliferation of malignant clonal hematopoietic stem)] TJ ET BT 35.000 365.362 Td /F1 12.0 Tf [(cells which can lead to anemia, neutropenia, and thrombocytopenia. If left untreated, AML can lead to)] TJ ET BT 35.000 350.710 Td /F1 12.0 Tf [(death within weeks. In the US, an estimated 19,940 new cases of AML were expected to be diagnosed)] TJ ET BT 35.000 336.058 Td /F1 12.0 Tf [(and approximately 11,180 deaths attributed to AML, nearly all in adults. AML is generally a disease of)] TJ ET BT 35.000 321.406 Td /F1 12.0 Tf [(the elderly with an average age of 68 years at the time of diagnosis and is more common in men than)] TJ ET BT 35.000 306.754 Td /F1 12.0 Tf [(women. For adults 65 years of age.)] TJ ET BT 35.000 276.070 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 246.879 Td /F1 12.0 Tf [(Treadwell Therapeutics is a clinical-stage multi-modality oncology company developing novel)] TJ ET BT 35.000 232.227 Td /F1 12.0 Tf [(medicines to address unmet needs in patients with cancer. The Company??s robust, internally)] TJ ET BT 35.000 217.575 Td /F1 12.0 Tf [(developed clinical pipeline includes CFI-400945, CFI-402257 \(TTK inhibitor\) and CFI-402411 \(HPK1)] TJ ET BT 35.000 202.923 Td /F1 12.0 Tf [(inhibitor\). Treadwell also has a robust pre-clinical pipeline with multiple biologic and next generation)] TJ ET BT 35.000 188.271 Td /F1 12.0 Tf [(TCR based autologous cell therapy programs. For more information, please visit www.treadwelltx.com.)] TJ ET BT 35.000 157.587 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 128.397 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 125.787 m 87.020 125.787 l S 0.000 0.000 0.800 rg BT 35.000 113.745 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 111.135 m 137.192 111.135 l S q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Annot /Subtype /Link /F 28 /A 12 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 111.4135 137.1920 123.6235 ] >> endobj 12 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 14 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 15 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 17 0 R ] /Contents 16 0 R >> endobj 16 0 obj << /Length 888 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 817.558 m 129.032 817.558 l S 0.000 0.000 0.800 rg BT 35.000 805.516 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 802.906 m 149.876 802.906 l S 0.000 0.000 0.000 rg BT 35.000 778.864 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 764.212 Td /F1 12.0 Tf [(April 26, 2022)] TJ ET q 35.000 761.282 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 803.1854 149.8760 815.3954 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com) >> endobj xref 0 19 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000644 00000 n 0000005580 00000 n 0000005687 00000 n 0000005796 00000 n 0000005909 00000 n 0000006042 00000 n 0000006119 00000 n 0000006176 00000 n 0000006233 00000 n 0000006357 00000 n 0000007297 00000 n 0000007430 00000 n trailer << /Size 19 /Root 1 0 R /Info 5 0 R /ID[<87faa2414112f5fa756a7e3457edf7b5><87faa2414112f5fa756a7e3457edf7b5>] >> startxref 7509 %%EOF